Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
691 stopped studies mapped to Malignant Head and Neck Neoplasm and descendants · 92% state a reason
Over the 691 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03740100 | Single-arm Study With Bimiralisib in Patients With HNSCC Harboring NOTCH1 Loss of…(HNSCC) | Phase 2 | terminated | Nov 14, 2018 | M.D. Anderson Cancer Center | The trial was closed because the sponsor became insolvent. | Other (stated, no rule matched) |
| NCT01824823 | Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous… | Phase 2 | terminated | Apr 5, 2013 | ECOG-ACRIN Cancer Research Group | Slow accrual | Enrollment / accrual |
| NCT02488629 | Study of SCB01A in Patient With Head and Neck Cancer | Phase 2 | terminated | Jul 2, 2015 | SynCore Biotechnology Co., Ltd. | not stated | Not stated |
| NCT04618432 | Collection of Clinical Data and Specimens for Research on Head and Neck and Communication… | — | terminated | Nov 6, 2020 | National Institute on Deafness and Other Communication Disorders (NIDCD) | PI moved institutes in NIH, and this protocol was redundant with an existing clinical protocol… | Other (stated, no rule matched) |
| NCT03522584 | Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With… | Phase 1 / Phase 2 | terminated | May 11, 2018 | University of Washington | Terminated by the sponsor due to lack of efficacy in study treatment. | Efficacy / futility |
| NCT04348916 | Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With… | Phase 1 | terminated | Apr 16, 2020 | Oncorus, Inc. | Terminated due to Oncorus portfolio reprioritization | Sponsor / business decision |
| NCT04987996 | GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell… | Phase 2 | withdrawn | Aug 3, 2021 | Providence Health & Services | Study withdrawn due to lack of supply of one of the investigational agents. | Drug supply |
| NCT03218475 | MRG FU With Radiotherapy for Palliation of H&N Cancer | N/A | suspended | Jul 14, 2017 | Sunnybrook Health Sciences Centre | On hold pending amendment approval | Other (stated, no rule matched) |
| NCT05743777 | PembROlizumab With or Without Microbial EcOsystem ThErapeutic 4 (MET4) in Advanced Head…(PROMOTE-HN) | Phase 2 | withdrawn | Feb 24, 2023 | Canadian Cancer Trials Group | Company withdrew financial support | Funding |
| NCT02345330 | Trial of pIL-12 Electroporation in Squamous Cell Carcinoma of the Head and Neck… | Phase 2 | terminated | Jan 26, 2015 | OncoSec Medical Incorporated | Due to company resource constraints | Sponsor / business decision |
| NCT03555721 | CytID Analysis of Oral Lesions | — | terminated | Jun 13, 2018 | The University of Texas Health Science Center, Houston | low subject recruitment | Enrollment / accrual |
| NCT03823131 | Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and… | Phase 2 | terminated | Jan 30, 2019 | Chase Heaton, MD | Treatment Ineffective | Other (stated, no rule matched) |
| NCT02698111 | Donafenib Monotherapy for Previously Treated Metastatic Nasopharyngeal Carcinoma | Phase 1 / Phase 2 | terminated | Mar 3, 2016 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Corporate policy adjustments | Other (stated, no rule matched) |
| NCT02376699 | Safety Study of SEA-CD40 in Cancer Patients | Phase 1 | terminated | Mar 3, 2015 | Seagen Inc. | Study closed due to portfolio prioritization | Sponsor / business decision |
| NCT03372148 | Role of Pharyngeal High Resolution Manometry and Impedance in Swallow Function of Head… | N/A | withdrawn | Dec 13, 2017 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Study withdrawn by PI | Other (stated, no rule matched) |
| NCT05220748 | RM-1995 Photoimmunotherapy, as Monotherapy or Combined With Pembrolizumab, in Patients… | Phase 1 | withdrawn | Feb 2, 2022 | Rakuten Medical, Inc. | Decision was made due to a strategic re-evaluation of pipelines; no patients were enrolled. | Enrollment / accrual |
| NCT03642990 | NR in Chemo-induced Peripheral Neuropathy | Phase 2 | terminated | Aug 22, 2018 | Donna Hammond, PhD | Enrollment challenges | Enrollment / accrual |
| NCT03544099 | Pembrolizumab for Nasopharyngeal Carcinoma Patients With Detectable Plasma Epstein-Barr… | Phase 2 | terminated | Jun 1, 2018 | National Health Research Institutes, Taiwan | Difficult to recruit Nasopharyngeal Carcinoma Patients With Detectable Plasma Epstein-Barr Virus DNA | Enrollment / accrual |
| NCT04110249 | Photoacoustic Imaging for Measuring Tumors and Normal Tissue in Patients With Head and… | N/A | terminated | Oct 1, 2019 | Roswell Park Cancer Institute | equipment issues | Other (stated, no rule matched) |
| NCT01332279 | Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With… | Phase 1 | withdrawn | Apr 11, 2011 | Fox Chase Cancer Center | Pharmaceutical co. withdrew support. Study was never activated and did not accrue any patients. | Enrollment / accrual |
| NCT01827709 | Pathological Validation of Functional Imaging in Head and Neck Squamous Cell Carcinoma | N/A | terminated | Apr 10, 2013 | Universitaire Ziekenhuizen KU Leuven | poor accrual | Enrollment / accrual |
| NCT03254927 | A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous… | Phase 2 | terminated | Aug 21, 2017 | Celldex Therapeutics | Sponsor decision based on emerging risk-benefit profile | Sponsor / business decision |
| NCT04034225 | Addition of SNS-301 to Checkpoint Inhibitor Treatment in Metastatic/Recurrent SCCHN | Phase 1 / Phase 2 | terminated | Jul 26, 2019 | Sensei Biotherapeutics, Inc. | Terminated by the sponsor | Other (stated, no rule matched) |
| NCT02582008 | Bupropion Hydrochloride or Patient's Choice for Smoking Cessation in Patients With… | Early Phase 1 | terminated | Oct 21, 2015 | Wake Forest University Health Sciences | Slow accrual | Enrollment / accrual |
| NCT02291055 | A Study of ADXS11-001 or MEDI4736 Alone or Combination In Cervical or Human… | Phase 1 / Phase 2 | terminated | Nov 14, 2014 | Advaxis, Inc. | not stated | Not stated |
| NCT02262221 | Health and Economic Outcomes of Two Different Follow up Strategies in Effectively Cured…(HETeCo) | N/A | suspended | Oct 13, 2014 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Low participant accrual | Enrollment / accrual |
| NCT02917629 | ACTOplus Met XR in Treating Patients With Stage I-IV Oral Cavity or Oropharynx Cancer… | Phase 2 | terminated | Sep 28, 2016 | National Cancer Institute (NCI) | Low accrual combined with expiration of study drug | Enrollment / accrual |
| NCT03435640 | REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With…(REVEAL) | Phase 1 / Phase 2 | terminated | Feb 19, 2018 | Nektar Therapeutics | Based on the overall results from the Phase 1 part of the study the sponsor decided to end the… | Safety / toxicity |
| NCT04996641 | Endodontic-Restorative Pre-Radiation Therapy of Head and Neck Cancer Patients(EndoRest) | N/A | withdrawn | Aug 9, 2021 | Abramson Cancer Center at Penn Medicine | Unable to enroll participants | Enrollment / accrual |
| NCT04868045 | Study of Resistance to Thyroid Hormone After Long-term Exposure in People With Thyroid… | Phase 1 | withdrawn | Apr 30, 2021 | Memorial Sloan Kettering Cancer Center | Lack of accrual | Enrollment / accrual |
| NCT02834247 | A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid… | Phase 1 | terminated | Jul 15, 2016 | Calithera Biosciences, Inc | Insufficient efficacy of drug; no safety concern | Safety / toxicity |
| NCT03193931 | Study Comparing Pembrolizumab With Methotrexate in Elderly, Frail or Cisplatin-ineligible…(ELDORANDO) | Phase 2 | terminated | Jun 21, 2017 | AIO-Studien-gGmbH | A very low recruitment rate made it impossible to reach the recruitment goal wthin an acceptable… | Enrollment / accrual |
| NCT02449681 | Study for Treatment of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of… | Phase 2 | terminated | May 20, 2015 | Rain Oncology Inc | Lack of efficacy | Efficacy / futility |
| NCT04969861 | BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent… | Phase 2 / Phase 3 | terminated | Jul 21, 2021 | Nektar Therapeutics | Nektar Therapeutics made the decision to discontinue the bempegaldesleukin program based on three… | Other (stated, no rule matched) |
| NCT05512767 | A Pneumatic Compression Device for the Treatment of Lymphedema in Patients With Stage… | N/A | withdrawn | Aug 23, 2022 | Mayo Clinic | PI retired and study not moving forward | Other (stated, no rule matched) |
| NCT04941365 | Quantifying Systemic Immunosuppression to Personalize Cancer Therapy(SERPENTINE) | N/A | withdrawn | Jun 28, 2021 | Institut du Cancer de Montpellier - Val d'Aurelle | please refer to NCT05621837 | Other (stated, no rule matched) |
| NCT04453046 | Hemopurifier Plus Pembrolizumab in Head and Neck Cancer | N/A | terminated | Jul 1, 2020 | Aethlon Medical Inc. | Lack of Eligible subjects at study site | Other (stated, no rule matched) |
| NCT05393635 | ITIL-168 in Advanced Solid Tumors(DELTA-2) | Phase 1 | withdrawn | May 26, 2022 | Instil Bio | business decision | Sponsor / business decision |
| NCT03982537 | Effect of N-Acetyl Cysteine (NAC) on the Oral Microbiome | Phase 2 | withdrawn | Jun 11, 2019 | Wake Forest University Health Sciences | Concept is withdrawn and a different concept will be submitted the near future. | Other (stated, no rule matched) |
| NCT03258008 | Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable… | Phase 2 | terminated | Aug 22, 2017 | M.D. Anderson Cancer Center | Closed the trial for infeasibility due to slow accrual | Enrollment / accrual |
| NCT05219578 | RTX-224 Monotherapy in Patients With Solid Tumors | Phase 1 / Phase 2 | terminated | Feb 2, 2022 | Rubius Therapeutics | The Sponsor terminated study after dosing 2 dose groups (7 pts) and closed trial on 11/30/22.… | Other (stated, no rule matched) |
| NCT04672980 | RTX-321 Monotherapy in Patients With HPV 16+ Tumors | Phase 1 | terminated | Dec 17, 2020 | Rubius Therapeutics | The Sponsor terminated study after dosing 3 dose groups (9 pts) and closed trial on 11/30/22.… | Other (stated, no rule matched) |
| NCT03513042 | Early Response Evaluation of Proton Therapy by PET-imaging in Squamous Cell Carcinoma…(ERM-PT-HNSCC) | — | terminated | May 1, 2018 | Leiden University Medical Center | Inclusionrate dropped due to changes in clinical process | Other (stated, no rule matched) |
| NCT04762225 | RPTR-168 in Patients With Human Papillomavirus Strain 16 (HPV-16) E6/E7 Positive Tumors… | Phase 1 | terminated | Feb 21, 2021 | Repertoire Immune Medicines | Development program terminated | Other (stated, no rule matched) |
| NCT05061940 | This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status… | — | terminated | Sep 30, 2021 | Repertoire Immune Medicines | Development program terminated | Other (stated, no rule matched) |
| NCT04155008 | Nutrition and Pharmacological Algorithm for Oncology Patients Study | Phase 4 | terminated | Nov 7, 2019 | Montefiore Medical Center | The trial was closed after 4 months due to slow to accrual. Only 1 participant was enrolled. | Enrollment / accrual |
| NCT03506048 | Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive… | Phase 2 | terminated | Apr 23, 2018 | Emory University | Study has been abandoned for lack of accrual | Enrollment / accrual |
| NCT02437916 | Safety Study of AMG 228 to Treat Solid Tumors | Phase 1 | terminated | May 8, 2015 | Amgen | not stated | Not stated |
| NCT04242173 | Cemiplimab-rwlc for Unresectable Locally Recurrent and/or Metastatic CSCC | Phase 2 | terminated | Jan 27, 2020 | H. Lee Moffitt Cancer Center and Research Institute | Lack of Interest | Other (stated, no rule matched) |
| NCT02055963 | Minocycline for Postsurgical Symptom Reduction in Head and Neck Cancer | Phase 2 | terminated | Feb 5, 2014 | M.D. Anderson Cancer Center | Early termination due to the protocol lack of progress in improving accrual rate | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jul 14, 2023source: clinicaltrials